DTaP-IPV-Hep B-Hib vaccine (Hexaxim®) : a review of its use in primary and booster vaccination (Q38075844)

28 August 2017

1 reference

title

DTaP-IPV-Hep B-Hib vaccine (Hexaxim®) : a review of its use in primary and booster vaccination (English)

1 reference

28 August 2017

Paul L McCormack

1 reference

28 August 2017

publication date

1 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

59-70

1 reference

Review of diphtheria, tetanus and pertussis vaccines in clinical development

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0007-7

Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0007-7

A DTaP-IPV//PRP∼T vaccine (Pentaxim): a review of 16 years' clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0007-7

Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0007-7

Low hepatitis B immunogenicity of a hexavalent vaccine widely used in Germany: results of the German Health Survey for Children and Adolescents, 2003-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0007-7

Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0007-7

Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0007-7

Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0007-7

Combined immunogenicity data for a new DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) following primary series administration at 2, 4, 6 months of age in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0007-7

Immunogenicity and Safety of an Investigational Hexavalent Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus-hepatitis B-Haemophilus influenzae B Conjugate Combined Vaccine in Healthy 2-, 4-, and 6-month-old Argentinean Infants

21 January 2018

1 reference

12 December 2020

Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 mon

1 reference

12 December 2020

1 reference

12 December 2020

Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years

1 reference

12 December 2020

Pertussis vaccines: WHO position paper

1 reference

12 December 2020

A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children

1 reference

12 December 2020

Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Th

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S40272-013-0007-7

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1016138450

0 references

1 reference